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The plant-based formulation, DCBT1234-LungKR
used in this study1 is not an Ayurvedic medicine.
Also, DCBT1234-LungKR contains hydro-alcoholic
extracts of three plants and is not a herbo-mineral
formulation. As part of the quality control efforts in
this part of the world, any plant-based formulation
studied by this group goes through mandatory
testing for heavy metals and pesticides. The final
finished formulation and each ingredient before
hydro-alcoholic extraction are screened for heavy
metal and pesticide toxicity before being adminis-
tered to the patients. The same was followed for
DCBT1234-LungKR formulation also. The batch used
in the trial had o1 ppm of mercury and arsenic,
o5 ppm of cadmium and aluminium and lead was
below detectable levels. Organophosphorous and
organochlorine pesticides were also not detected.
Serum analysis in patients was thus not done.
We would like to cite here that salbutamol (2mg)
in combination with theophylline (100mg) was used
in one study and their synergistic effect was
superior to other forms of treatment.2 However,
the two studies3,4 cited by the author in his letter
to the editor the number of patients in both the
study are just 9 and 12. While mentioning this, it
must be agreed that the point raised by the author
on GOLD standards was also pointed out by the
Respiratory Medicine referees and one of them also
opined that it was a practice in India to use
salbutamol, theophylline and bromhexine for the
treatment of COPD. In our study, we decided to
follow what was in practice in the hospital where
the trial was being carried out for the treatment of
COPD.
We also would like to bring to the author’s
attention that in our trial, we have observed at the
end of the study that inhaled bronchodilators were
used to the same extent in both the DCBT1234-ee front matter & 2006 Elsevier Ltd. All rights reserv
med.2006.02.027LungKR and biomedical arms as relief medication
(data not presented in the Respiratory Medicine
article).
The protocol has a 12-min walking distance
measurement as one of the criteria for improve-
ment (data not presented in the Respiratory
Medicine article). We also have data based on the
severity (GOLD standard) of the disease. Both the
data along with the other un-published data of this
trial is presently under compilation for publication.References
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